CNBC Halftime Report
2026-09-09 · Hosted by Scott Wapner · CNBC
Executive Summary
The Investment Committee debated a market pressing against strong earnings tailwinds even as oil, yields, and Fed-hike odds all rose. Scott Wapner framed the setup as earnings strength on one side of the scale outweighing oil, yields, and Fed risk on the other, a framing Joe Terranova endorsed while Jim Lebenthal pushed back, arguing diesel prices (not just crude) are the real inflation risk with no earnings catalysts due until October. The market currently prices roughly a 60% chance of a 25-basis-point Fed hike at the September 16 meeting, which the desk broadly doubted would happen or would help even if it did.
Key Stories & Changes
1. Market Setup: Earnings vs. Oil, Yields, and Fed Risk
Oil at highest since June; global energy ETF at an all-time high; talk of $120/barrel if Middle East tensions intensify
10-year yield elevated; market pricing roughly 60% odds of a 25-basis-point Fed hike on September 16
Scott Wapner's framing: earnings strength outweighs oil/yield/Fed risk "if not outweighs them," a view Joe Terranova called "accurately stated"
Jim Lebenthal pushed back, arguing diesel (not crude) is the bigger inflation threat, with no earnings news to offset it until October
Sell-side notes cited: HSBC S&P target of 8,100 on earnings strength; Deutsche Bank sentiment turned bullish for the first time in seven weeks; UBS still bullish, calling growth "not fully priced in"
2. Qualcomm-Amazon Deal Reaction
Committee generally positive on the strategic diversification (Qualcomm moving into data centers, away from smartphone reliance) but split on trading it
Jim Lebenthal: tempted to buy but holding off given "heavy" September seasonality; needs price below $196 to offset embedded gains after trimming near $230
Joe Terranova: noted several prior Qualcomm data-center announcements this year didn't move the stock much, expressed some surprise the reaction wasn't larger given how poorly the stock had traded since May
Brian Belski: called it "one heck of a base warning" technically and a cheap stock worth adding to, just not in September
3. Mag 7 Resurgence and Valuation Debate
Mag 7 basket had underperformed the S&P by a wide margin June-July before narrowing to roughly even with the index
Nvidia trading near an all-time high at roughly 19x forward earnings (next year's expected profit); revenue growth guided at 70%, described as supply-constrained
Microsoft cited as a sentiment turnaround story, having traded under $400 a few months ago
Jim Lebenthal flagged Nvidia's price-to-earnings multiple (17.5x cited) as elevated relative to its market weight, comparing cautiously to 1999-2000 dot-com peak multiples of 30-35x on the broader S&P
4. Apple Ahead of Wednesday's Event
Foldable iPhone priced between roughly $2,100 and $3,000; BTIG data shows Apple has been negative in September 7 of the last 10 years, averaging -3.15%
Joe Terranova: argues the launch is fully priced in; sees the next earnings report (heading into holiday season) as the real catalyst, not the product event itself
Jim Lebenthal: more constructive, drawing a parallel to Tim Cook's 2020 China trip that inspired the original foldable push, and floating a future foldable iPad
Stock has had a "series of higher lows" since post-earnings weakness; trading around $315 versus an all-time high near $334
Analyst backdrop mixed: Moffett Nathanson Neutral ($380 target cited for a separate name), Needham cautious
5. Healthcare: Novartis Fallout and Sector Views
Novartis: muscle-wasting drug (tied to ~$12B Avidity Biosciences acquisition) failed to meet its main late-stage goal; a separate cholesterol drug also failed a Friday phase 3 readout on cardiovascular outcomes
Amgen fell roughly 10% in sympathy (competing GLP/cholesterol drug exposure); downgraded to Hold from Buy at BMO with a $50 price target cited
AstraZeneca posted full phase 3 COPD data showing benefit across a broad population including previously ineligible patients; CEO told CNBC the drug could see over $5 billion in peak annual sales
Brian Belski's firm favors J&J and Merck as best-positioned large pharma names, cautious on Pfizer; holds AbbVie (reiterated $282 target)
Jim Lebenthal noted medical devices (Stryker, Baxter, Intuitive Surgical) are underperforming due to lack of revenue growth, while GLP-adjacent names need double-digit revenue growth to justify inclusion
6. Oracle Earnings Preview (Thursday)
Committee holds Oracle as a core position; expects 33% year-over-year top-line growth for the fiscal year ending in May
Key focus: clarity on CapEx funding mechanism (currently ~$70 billion) and whether the company raises that number
Five-year credit default swaps cited above 200 basis points; watching whether that widens further
Abilene, Texas data center coming online seen as a margin-trajectory data point
7. Calls of the Day
SHAK: Shake Shack — Outperform initiation, RBC — $89 price target; framed as a Gen Z-focused secular growth thematic play
SBUX: Starbucks — Discussed alongside Shake Shack — Seen as an operational turnaround story under new leadership
ABNB: Airbnb — Upgraded to Outperform — $200 price target; cited resilient travel demand and post-earnings price momentum not seen since 2020
Trends Identified
1. Earnings Strength as the Market's Primary Justification for Risk-Taking
Despite rising oil, yields, and Fed-hike odds, the committee repeatedly returned to earnings durability as the dominant reason markets have held up, with strategist notes (HSBC, Deutsche Bank, UBS) reinforcing a bullish institutional consensus even amid rising macro noise.
2. Data-Center Diversification Reshaping Chip Supplier Dynamics
Qualcomm's AWS deal is the latest in a series (per Terranova, roughly the third such announcement this year) of hyperscalers diversifying chip suppliers beyond Nvidia. The committee's mixed reaction — structurally bullish but tactically cautious — reflects uncertainty about how quickly these deals translate into stock performance versus prior announcements that fizzled.
3. September Seasonality as a Behavioral Anchor, Not a Fundamental Signal
Both Lebenthal and Belski explicitly cited September's historically weak seasonality (for the S&P broadly and for Apple specifically) as a reason to delay adding to positions they otherwise like, even while acknowledging the statistical sample size is small and "not very statistically significant."
4. Healthcare Bifurcation Between Growth and Value
Belski's insistence on double-digit revenue growth as a screening criterion for healthcare holdings, contrasted with Lebenthal's observation that medical devices are lagging without that growth, illustrates a sector rotation toward names with clear pipeline-driven growth (AbbVie, Merck, J&J) and away from legacy device makers. ---
Sentiment Analysis
Overall Market Sentiment: Constructive but Watchful
The committee leaned bullish on the earnings backdrop but flagged near-term technical/seasonal caution, particularly around September positioning in AI infrastructure and Apple names.
Risk Factors Highlighted
Diesel price surge: Lebenthal specifically flagged diesel (not just crude) as a record-high, non-abating inflation risk with wide economic reach (shipping, farming, freight).
Fed rate-hike uncertainty: ~60% market-implied odds of a 25bp hike on September 16 create a binary near-term catalyst the committee broadly doubts will materialize as expected.
September seasonality: Historically the weakest month for both the S&P and Apple specifically, cited as a reason for tactical caution even amid bullish long-term views.
Novartis/Amgen trial failures: Back-to-back late-stage failures triggered a sector-wide selloff and a rating downgrade for Amgen.
Oracle CapEx funding clarity: Investors want confirmation Oracle won't raise its ~$70 billion CapEx further without matching funding clarity; CDS spreads already elevated above 200bps.
Valuation concerns in mega-cap tech: Lebenthal flagged Nvidia's forward multiple relative to rising yields as a risk if yields continue backing up.
Medical device sector weakness: Lack of revenue growth in Stryker, Baxter, and Intuitive Surgical was flagged as a red flag within otherwise-favored healthcare.
This episode was covered in today's [The Market Signal — 2026-09-09](https://marketsignal.beehiiv.com/p/the-market-signal-2026-09-09), a cross-source synthesis of multiple podcast reports.